Teva launches breath-activated asthma aerosol in U.S.
Teva Pharmaceuticals (NYSE:TEVA) has launched its Qvar RediHaler inhalation aerosol in the U.S., marking the first time a breath-actuated inhaled corticosteroid is available for asthma patients as a prophylactic therapy. In contrast to traditional metered-dose inhalers, Teva’s Qvar RediHaler sends medication into the user’s lungs as they inhale. This feature eliminates the need for hand-breath coordination, according to Teva. Get the full story at our sister site, Drug Delivery Business News. The post Teva launches breath-activated asthma aerosol in U.S. appeared first on MassDevice.
Conclusion: Asthma is common among patients presenting with a principal symptom of dyspnea in the ED of the Asia Pacific region. There was suboptimal adherence to international guidelines on investigations and treatments of acute asthma exacerbations presenting an opportunity to improve efficiency of care. This article is protected by copyright. All rights reserved.
This study was aimed at evaluating whether once-daily regimens (od-r) show benefits in adherence when compared to twice-daily (td-r). METHODS: Prospective, multicenter, 6-month follow-up study with two visits. The main objective was to compare adherence assessed by the electronic prescription refill rate (EPRR) and by the 10-item Test of Adherence to Inhalers (TAI) in patients with od-r and td-r. Suboptimal adherence was defined as TAI
ConclusionsAll Pediatric Self‐Management Model domains were correlated with youth adherence, which suggests medication adherence is influenced across multiple systems; however, most studies assessed adherence correlates within a single domain. Future research is needed that cuts across multiple domains to advance understanding of determinants of adherence.
We thank Dr. Weinberger for the interest in our publication “Dexamethasone for inpatient childhood asthma exacerbations is as effective as short-acting corticosteroid treatment.”1 The growing number of studies in this area reflects the importance of refining our approach to treating children with acute asthma exacerbations, the most common reason for chi ldhood hospitalizations in the U.S.2 We believe our report fills an important knowledge gap by answering the question whether a two-dose dexamethasone regimen is as effective as short-acting systemic corticosteroid for hospitalized children.
AbstractEosinophilic esophagitis and asthma are frequently found as comorbid conditions in children and adults along with other manifestations of atopic diathesis. These two conditions have similar T helper 2 responses-driven pathophysiology and share common management strategies such as using systemic corticosteroids and targeted anti-cytokine biologic therapies. Review of the literature finds that asthma is often a comorbid condition in eosinophilic esophagitis in both children and adults; however, the EoE-asthma relationship remains poorly characterized mechanistically and clinically. EoE and asthma commonly share sever...
Abstract The epithelial cytokines IL-33, thymic stromal lymphopoietin (TSLP), and IL-25 have been implicated in asthma pathogenesis because they promote Th2-type cytokine synthesis, but their expression is relatively poorly documented in "real-life" human asthma. Using bronchoalveolar lavage fluid (BALF), we measured airway concentrations of these mediators and compared them with those of Th1- and Th2-type cytokines, airway infiltration of neutrophils and eosinophils, and lung function in a large group of asthmatic patients with a range of disease severity (n = 70) and control subjects (n = 30). The medi...
CONCLUSIONS: Within a high-risk pediatric cohort, electronic monitoring of ICS use and adherence reminders delivered via text message were feasible for most participants, but there was no signal of effect. Adherence trajectories following severe exacerbation were suboptimal, demonstrating an important opportunity for asthma care improvement. PMID: 29437489 [PubMed - as supplied by publisher]
CONCLUSION: Emerging therapies currently in development may provide more consistent benefit to patients with allergic diseases by specifically targeting inflammatory pathways important for disease pathogenesis. PMID: 29454096 [PubMed - as supplied by publisher]
In conclusion, we found that early montelukast discontinuation increased during the last 19 years. Appropriateness of the treatment indication as estimated by concomitant prescription of adequate inhalation therapy was associated with a low risk of early discontinuation. A more pronounced early discontinuation was observed after patent expiry in 2012, which could reflect a more liberal approach to montelukast prescription. This article is protected by copyright. All rights reserved.
Traditional corticosteroid inhalers for management of asthma symptoms require patients to squeeze and inhale in a coordinated maneuver. This is surprisingly difficult for many patients who end up receiving sub-optimal treatment. Teva Pharmaceutical, ...